Dilman V M, Berstein L M, Zabezhinski M A, Alexandrov V A, Bobrov J F, Pliss G B
Arch Geschwulstforsch. 1978;48(1):1-8.
It is shown that daily oral administration of 5--10 mg of an antidiabetic biguanide-phenformin (phenethyl-biguanide) for 2.5--5 months suppressed DMBA-induced mammary tumour development in rats considerably. Phenformin-treated rats revealed-a tendency towards a decrease in blood insulin level (radioimmunoassay). The obtained data are regarded as additional evidence for the proposed existence of the same metabolic background of diseases of compensation, i.e. adult-onset diabetes, artherosclerosis and cancer, and suggest studies on possible antitumour effect of phenformin in man.
结果表明，每日口服5 - 10毫克抗糖尿病双胍类药物苯乙双胍（苯乙基双胍），持续2.5 - 5个月，可显著抑制二甲基苯蒽（DMBA）诱导的大鼠乳腺肿瘤发展。用苯乙双胍治疗的大鼠显示出血液胰岛素水平有下降趋势（放射免疫测定法）。所获数据被视为进一步证据，支持所提出的代偿性疾病，即成年型糖尿病、动脉粥样硬化和癌症存在相同代谢背景的观点，并提示应对苯乙双胍对人体可能的抗肿瘤作用进行研究。
